THE IMMUNE RESPONSE OF RABBITS TOLERANT TO BOVINE SERUM ALBUMIN TO THE INJECTION OF OTHER HETEROLOGOUS SERUM ALBUMINS
THE IMMUNE RESPONSE OF RABBITS TOLERANT TO BOVINE SERUM ALBUMIN TO THE INJECTION OF OTHER HETEROLOGOUS SERUM ALBUMINS
复制标题
牛血清白蛋白耐受家兔对注射其他异源血清白蛋白的免疫反应
DOI：
--
复制
发表时间：
1961
影响因子：
15.3
通讯作者：
W. Weigle
中科院分区：
文献类型：
--
作者：
W. Weigle
通过注射一系列与 BSA 发生交叉反应的异源血清白蛋白，可以终止新生儿注射 BSA 所产生的免疫耐受性。注射与 BSA 关系较远的白蛋白比注射与 BSA 关系密切的白蛋白更能有效终止耐受状态。从用几种异源白蛋白获得的结果得出的结论是，对 BSA 的免疫耐受性涉及蛋白质的整体抗原或物理化学组成以及蛋白质上存在的各个决定簇。给出了几种可能的机制来解释交叉反应白蛋白终止 BSA 耐受兔的耐受状态的能力。讨论了注射交叉反应白蛋白的 BSA 耐受兔的耐受终止与自身免疫之间可能的关系。还表明，与细菌抗原相比，相对容易建立对异源血清蛋白的耐受性是异源血清蛋白与兔血清蛋白密切的血清学和物理化学关系的结果。在生命的前 5 天注射 500 毫克 BSA 的兔子未能形成能够引发免疫消除 3 至 4 个月后注射的 I* BSA 或与循环 I* BSA 复合的抗体。
Immunological tolerance produced in rabbits by neonatal injections of BSA can be terminated by a series of injections of certain heterologous serum albumins which cross-react with BSA. Injections of albumins distantly related to BSA were more effective in terminating the tolerant state than injections of albumins closely related to BSA. It was concluded from results obtained with several heterologous albumins that immunological tolerance to BSA is directed to both the over-all antigenic or physical-chemical composition of the protein and the individual determinant groups present on the protein. Several possible mechanisms were given to explain the ability of cross-reacting albumins to terminate the tolerant state of BSA-tolerant rabbits. A possible relationship between the termination of tolerance in BSA-tolerant rabbits injected with cross-reacting albumins and autoimmunily was discussed. It was also suggested that the relative ease with which tolerance could be established to heterologous serum proteins in comparison to bacterial antigens is the result of the close serological and physical-chemical relationship of the heterologous serum proteins to the serum proteins of the rabbit. Rabbits injected with 500 mg of BSA during the first 5 days of life failed to form antibody capable of either eliciting an immune elimination of an injection of I* BSA given 3 to 4 months later or complexing with the circulating I* BSA.